Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials

Sabe, Michel; Kirschner, Matthias; Kaiser, Stefan

doi:10.1097/JCP.0000000000001124

Scientific article

Review

English

Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials

ContributorsSabe, Michel; Kirschner, Matthias; Kaiser, Stefan

Published inJournal of Clinical Psychopharmacology, vol. 39, no. 6, p. 658-664

Publication date2019

Abstract

The negative symptoms of schizophrenia pose a heavy burden on patients and relatives and represent an unmet therapeutic need. The observed association of negative symptoms with impaired reward system function has stimulated research on prodopaminergic agents as potential adjunctive treatments.

Keywords

Prodopaminergic
Stimulants
Schizophrenia
Negative symptoms
Amotivation

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de psychiatrie

Research groups

Psychopathologie clinique et expérimentale (987)

Citation (ISO format)

SABE, Michel, KIRSCHNER, Matthias, KAISER, Stefan. Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials. In: Journal of Clinical Psychopharmacology, 2019, vol. 39, n° 6, p. 658–664. doi: 10.1097/JCP.0000000000001124

Article (Published version)

Identifiers

PID : unige:132681
DOI : 10.1097/JCP.0000000000001124
PMID : 31688399

Journal ISSN0271-0749

350views

1downloads

Creation29/01/2020 11:24:00

First validation29/01/2020 11:24:00

Update13/10/2025 17:34:08

Status update15/03/2023 21:17:30

Last indexation11/02/2026 10:52:40

Archive ouverte UNIGE

Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials

The negative symptoms of schizophrenia pose a heavy burden on patients and relatives and represent an unmet therapeutic need. The observed association of negative symptoms with impaired reward system function has stimulated research on prodopaminergic agents as potential adjunctive treatments.

Technical informations